Metastasis
Most cancer-associated deaths occur due to metastasis, yet our understanding of metastasis
as an evolving, heterogeneous, systemic disease and of how to effectively treat it is still …
as an evolving, heterogeneous, systemic disease and of how to effectively treat it is still …
The oligometastatic spectrum in the era of improved detection and modern systemic therapy
Metastases remain the leading cause of cancer-related mortality. The oligometastasis
hypothesis postulates that a spectrum of metastatic spread exists and that some patients …
hypothesis postulates that a spectrum of metastatic spread exists and that some patients …
Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial
PURPOSE The oligometastatic paradigm hypothesizes that patients with a limited number of
metastases may achieve long-term disease control, or even cure, if all sites of disease can …
metastases may achieve long-term disease control, or even cure, if all sites of disease can …
Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): extended long-term outcomes
Purpose Long-term randomized data assessing the effect of ablative therapies in patients
with oligometastases are lacking. The Stereotactic Ablative Radiotherapy for the …
with oligometastases are lacking. The Stereotactic Ablative Radiotherapy for the …
Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis
Importance The oligometastatic paradigm postulates that patients with a limited number of
metastases can be treated with ablative local therapy to each site of disease with curative …
metastases can be treated with ablative local therapy to each site of disease with curative …
Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study
Background Stereotactic ablative body radiotherapy (SABR) is increasingly being used to
treat oligometastatic cancers, but high-level evidence to provide a basis for policy making is …
treat oligometastatic cancers, but high-level evidence to provide a basis for policy making is …
Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial
Background A recent randomized phase II trial evaluated stereotactic ablative radiotherapy
(SABR) in a group of patients with a small burden of oligometastatic disease (mostly with 1 …
(SABR) in a group of patients with a small burden of oligometastatic disease (mostly with 1 …
Radiotherapy and immunology
The majority of cancer patients receive radiotherapy during the course of treatment,
delivered with curative intent for local tumor control or as part of a multimodality regimen …
delivered with curative intent for local tumor control or as part of a multimodality regimen …
Approaches to the management of metastatic adenoid cystic carcinoma
Simple Summary Patients with adenoid cystic carcinoma (ACC) often experience late distant
metastasis years after definitive therapy, most commonly to the lungs. Currently, there is little …
metastasis years after definitive therapy, most commonly to the lungs. Currently, there is little …
Oligometastases: emerging evidence
The hypothesis that ablative therapies (such as surgery or radiation) can be used to cure
patients with a limited number of metastases was influential in changing practice. Early …
patients with a limited number of metastases was influential in changing practice. Early …